Have you heard of the US stock Royalty Pharma (ticker symbol: RPRX)?
It is a company that invests in new drugs and helps the biopharmaceutical industry to innovate.
In this article, I will introduce the company’s financial results for the period April to June 2021, which were announced on August 10, 2021.
Financial Results for April to June 2021
The equivalent of sales for a normal company is adjusted cash receipts (ACR).
ACR was $475 million, up 3% from the same period last year. In the same period last year, it was $462 million.
The equivalent of ordinary corporate profits is non-GAAP adjusted cash flow (ACF).
ACF was $429 million, up 16% from the same period last year. In the same period last year, it was $369 million. On a per share basis, ACF was 71¢. In the same period last year, it was 61¢ per share.
The number of royalty acquisitions in the past 12 months was 26, up 73%. In the same period last year, there were 15.